Insulin glulisine (Apidra)

What insulin glulisine is and how it works

Insulin glulisine is a rapid-acting insulin analogue used by adults and children with diabetes mellitus to help control blood glucose (sugar) levels. It is injected under the skin, usually shortly before a meal, and starts working faster than regular human insulin. (1) (2)

Insulin glulisine helps your body move glucose from the blood into cells for energy, closely mimicking the natural, fast insulin response to a meal. It is prescribed and dosed individually by a clinician, and its rapid onset means timing around meals matters. It carries genuine, serious warnings about low blood sugar (hypoglycaemia), low blood potassium (hypokalaemia), and about never sharing insulin delivery devices between people.

Mechanism of action: how insulin glulisine works

Insulin glulisine is a recombinant human insulin analogue that differs from human insulin by small structural changes that reduce self-association, allowing faster absorption from the subcutaneous injection site and a more rapid onset and shorter duration of action than regular human insulin. (1) (4)

What insulin glulisine is used for

Before taking insulin glulisine

Do not take / not appropriate for

• Do not use insulin glulisine during an episode of hypoglycaemia (low blood sugar). (all countries where authorised) (1) (2)
• Do not use if you have had a serious allergic reaction to insulin glulisine or any of its ingredients. (all countries where authorised) (1) (2)

Tell your clinician about

• Any history of severe or frequent low blood sugar (hypoglycaemia), or reduced awareness of hypoglycaemia symptoms.
• Any kidney or liver problems, which can affect how much insulin you need.
• Any heart problems, especially if you also take pioglitazone or another PPAR-gamma agonist diabetes tablet, since fluid retention and heart failure have been reported with combined use.
• If you use an insulin pump, and how to recognise and respond to pump malfunction (which can lead to high blood sugar and ketoacidosis).
• All other medicines you take, since many can affect blood sugar control.
• Whether you are pregnant, planning pregnancy, or breastfeeding.
• Which specific Apidra product and strength you have been prescribed, since accidental mix-ups between insulin products have been reported.

How to take insulin glulisine

• Inject under the skin (subcutaneously) in the abdomen, thigh, or upper arm/deltoid as advised by your clinician, usually shortly before a meal because of its fast onset of action.
• Rotate injection sites within the same region to reduce the risk of skin changes (lipodystrophy) and localised cutaneous amyloidosis at the injection site.
• NEVER share prefilled pens, cartridges, or reusable pens with another person, even if you change the needle. If you use vials, NEVER share needles or syringes with another person. Sharing carries a real risk of transmitting blood-borne infections such as hepatitis or HIV. (This specific warning is explicit in the current US and Canadian labels; it was not found verbatim in the current UK, Australia, or New Zealand label text reviewed, but the underlying biological risk applies to any shared injection device.)
• Only your clinician should change your insulin dose, brand, or regimen -- do not switch products or adjust your dose yourself.
• Always check you have the correct Apidra product and strength before injecting.
• If using cartridges, only use pens the manufacturer confirms are compatible -- dosing accuracy has only been established with specific compatible pens.

Procedures and treatment changes

Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (1) (2) (3) (4) (5) (6)

Missed dose

Contact your prescriber or diabetes care team for individual guidance on a missed dose, since timing relative to meals and blood glucose matters, and never take an extra dose to make up for a missed one without specific instructions.

Overdose

Seek urgent medical attention if you think you have taken too much insulin glulisine, or if you develop signs of severe low blood sugar (confusion, sweating, shakiness, difficulty speaking, seizures, or loss of consciousness) -- follow your emergency hypoglycaemia plan and treat low blood sugar promptly as advised by your clinician. (1)

Side effects

Side effects and their urgency vary; report severe, persistent, or concerning symptoms.

Serious warnings

Interactions

• Many other medicines can affect blood glucose control (raise or lower insulin needs), including some diabetes tablets, ACE inhibitors, angiotensin II receptor blockers, and salicylates -- tell your clinician about all medicines you take so your insulin dose can be adjusted appropriately. (1)
• Pioglitazone and other PPAR-gamma agonist diabetes tablets (thiazolidinediones) combined with insulin can cause fluid retention and heart failure, particularly in patients with existing heart problems. (2) (1)
• Alcohol can affect blood glucose control and increase the risk of hypoglycaemia. (1)
• Beta-blockers, clonidine, and some other medicines can mask or blunt the usual warning symptoms of hypoglycaemia, making it harder to notice. (1)

Pregnancy, breastfeeding, kidney/liver function, age

Monitoring

Before starting

• Baseline blood glucose control (e.g. HbA1c)
• Kidney and liver function if relevant
• Personal history of hypoglycaemia awareness/severity
• Cardiac status if using with pioglitazone or another PPAR-gamma agonist

During treatment

• Regular self-monitoring of blood glucose as directed by your clinician.
• Prompt recognition and treatment of hypoglycaemia; carry a fast-acting source of sugar.
• Periodic review of injection sites for signs of skin changes.
• Monitoring for signs of hypokalaemia in at-risk patients.
• Insulin pump users: monitoring for signs of pump malfunction and resulting hyperglycaemia/ketoacidosis.

Storage

Store unopened Apidra in a refrigerator (2-8C); do not freeze or expose to excessive heat or direct sunlight, and keep in the outer carton to protect from light. Once in use, vials, cartridges, and prefilled pens can be kept at room temperature (below 25C, away from heat and light) and should be discarded after 28 days, whether or not they were kept refrigerated during that time.

Frequently asked questions

References

1. APIDRA (insulin glulisine) injection -- full prescribing informationU.S. Food and Drug Administration / DailyMed (NIH), full prescribing information, Sanofi-Aventis U.S. LLC · United States · accessed 2026-07-31 · source 1
2. Apidra 100 Units/ml solution for injection in a vial -- Summary of Product Characteristicselectronic medicines compendium (emc), United Kingdom -- Sanofi (Aventis Pharma Limited) · United Kingdom · accessed 2026-07-31 · source 2
3. Apidra, INN-insulin glulisine -- EPAR summary for the public / medicine overviewEuropean Medicines Agency (EMA) -- EPAR for Apidra · European Union · accessed 2026-07-31 · source 3
4. APIDRA (insulin glulisine injection, rDNA origin) -- Product Monograph, including Patient Medication InformationHealth Canada product monograph, sanofi-aventis Canada Inc. · Canada · accessed 2026-07-31 · source 4
5. APIDRA insulin glulisine (rbe) -- ARTG entries (vial 99145, cartridge 99146, SoloStar pen 132816) and current Product InformationTherapeutic Goods Administration (TGA) / medsinfo.com.au, Australia -- sanofi-aventis australia pty ltd · Australia · accessed 2026-07-31 · source 5
6. Apidra / Apidra SoloStar (insulin glulisine) -- New Zealand Data SheetMedsafe (New Zealand regulator) · New Zealand · accessed 2026-07-31 · source 6

Brand names by country

Single-ingredient insulin glulisine names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.

Priority countries